SESSION III: THE SPECIALTY PHARMACEUTICALS MARKETPLACE: IS PRICE - - PowerPoint PPT Presentation
SESSION III: THE SPECIALTY PHARMACEUTICALS MARKETPLACE: IS PRICE INELASTICITY SUSTAINABLE? Headlines Exclusive Costs to public of $84,000 hp C Drug outreageous- Kaiser.
“Exclusive Costs to public of $84,000 hp C Drug outreageous-Kaiser.” http://www.reuters.com/article/2014/04/02/us-hepatitisc-gilead-sciences- idUSBREA311Y120140402, accessed 2/9/2015
“$1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices”
http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c- spurs-debate-over-drug-prices. Published December 30,2013, accessed 2/10/2015.
Source: http://www.nytimes.com/interactive/2013/03/19/business/for-some-spending-less-on-drugs.html
Hirsch, Bradford R., Suresh Balu, and Kevin A. Schulman. "The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs." Health Affairs 33.10 (2014): 1714-1720.
Population and Personalized Medicine in the Modern Era
Chapman, Paul B., et al. "Improved survival with vemurafenib in melanoma with BRAF V600E mutation." New England Journal of Medicine 364.26 (2011): 2507-2516.
Sabatine MS et al. N Engl J Med 2015;372:1500-1509; Robinson JG et
Hirsch, Bradford R., Suresh Balu, and Kevin A. Schulman. "The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs." Health Affairs 33.10 (2014): 1714-1720.
150 120
90 60 30
Warden, 2005
MODERATOR Kevin Schulman Duke University PANEL Justin Klein NEA Richard Evans Head of Healthcare Practice SSR LLC Sean Tunis Center for Medical Technology Policy Julie Stoss Kaiser Permanente